Kaare Bjerregaard-Andersen received a PhD from Oslo University in Norway (2014), where he characterized the structure of membrane proteins, in particular the intrinsically disordered regions within a regulatory domain of a bicarbonate transporter (SLC4A10, NBCn2). He also developed an enzymatic assay for a metabolite called isatin, with the aim of facilitating its development as a biomarker. As a postdoctoral fellow, he continued to investigate protein structures, including how antibodies recognize antigens, with a specific focus on engineering the antigen-binding site of a tumor-associated glyco-antigen recognizing antibody (14F7). Now as a senior research scientist at Lundbeck in Copenhagen, Denmark, where he’s been since 2018, Dr. Bjerregaard-Andersen combines all of his previous roles focusing on alpha-synuclein structural biology and pathology, development of a seed amplification assay for aggregated alpha-synuclein as a biomarker and acting as a project leader on an early program to develop pathology-specific antibodies.